View details of this raise on Seedstage

Indianapolis, IN

Developing peptide-based solutions for sleep and longevity through innovative formulations.

• Peptide Innovation: Carnyx Therapeutics is creating novel peptide formulations to improve health outcomes.
• Oral and Eye Drop Formulations: The company is developing non-injection methods for peptide delivery to enhance patient compliance.
• Experienced Leadership: Led by Dr. Patrick Gunning, who has a track record of successful biotech ventures.
• Targeting Sleep and Vision: Focusing on sleep disorders and retinitis pigmentosa with proprietary Epitalon analogs.
• Growing Market Potential: The peptide therapeutics market is projected to reach $260 billion by 2030.

Carnyx Therapeutics is developing a novel approach to peptide-based medicine, focusing on the optimization and approval of Epitalon, a peptide with potential applications in sleep improvement and longevity. The company aims to address the limitations of traditional peptide administration by creating oral and eye drop formulations, which could significantly enhance patient accessibility and compliance.

Led by Dr. Patrick Gunning, Carnyx Therapeutics is leveraging decades of research on Epitalon to create proprietary analogs that target specific health issues such as sleep disorders and retinitis pigmentosa. The company’s strategy involves conducting IND-enabling studies and pursuing FDA approval to validate the safety and efficacy of their formulations. By improving the delivery and stability of Epitalon, Carnyx Therapeutics seeks to capture a share of the growing peptide therapeutics market, which is projected to reach $260 billion by 2030.

Company Info

Carnyx Therapeutics is developing peptide-based therapeutics to improve sleep and vision, focusing on oral and eye drop formulations of Epitalon.

Carnyx Therapeutics is a biotech company focused on developing peptide-based therapeutics, particularly targeting the sleep and vision markets. The company aims to improve and validate the safety and efficacy of Epitalon, a peptide known for its potential to enhance sleep and longevity, by creating novel analogs that can be administered orally or via eye drops, thus avoiding the need for injections.

Led by Dr. Patrick Gunning, Carnyx is leveraging its expertise in molecular chemistry to optimize Epitalon for specific medical indications. The company is currently in the pre-clinical stage, working towards IND-enabling studies for its sleep and vision formulations, with the goal of entering Phase I trials. Carnyx’s approach includes filing patents for its unique formulations, aiming to secure a competitive edge in the growing peptide therapeutics market.